Literature DB >> 9593160

Postantibiotic effect and postantibiotic sub-MIC effect of levofloxacin compared to those of ofloxacin, ciprofloxacin, erythromycin, azithromycin, and clarithromycin against 20 pneumococci.

S K Spangler1, G Lin, M R Jacobs, P C Appelbaum.   

Abstract

The postantibiotic effect (PAE) (10 times the MIC of quinolones, 5 times the MIC of macrolides) and postantibiotic sub-MIC effect (PAE-SME) at 0.125, 0.25, and 0.5 times the MIC were determined for levofloxacin, ciprofloxacin, ofloxacin, erythromycin, azithromycin, and clarithromycin against 20 pneumococci. Quinolone PAEs ranged between 0.5 and 6.5 h, and macrolide PAEs ranged between 1 and 6 h. Measurable PAE-SMEs (in hours) at the three concentrations were 1 to 5, 1 to 8, and 1 to 8, respectively, for quinolones and 1 to 8, 1 to 8, and 1 to 6, respectively, for macrolides.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9593160      PMCID: PMC105793          DOI: 10.1128/AAC.42.5.1253

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  19 in total

Review 1.  Treatment and diagnosis of infections caused by drug-resistant Streptococcus pneumoniae.

Authors:  M R Jacobs
Journal:  Clin Infect Dis       Date:  1992-07       Impact factor: 9.079

2.  In vitro activity of S-ofloxacin.

Authors:  H C Neu; N X Chin
Journal:  Antimicrob Agents Chemother       Date:  1989-07       Impact factor: 5.191

Review 3.  Antimicrobial resistance in Streptococcus pneumoniae: an overview.

Authors:  P C Appelbaum
Journal:  Clin Infect Dis       Date:  1992-07       Impact factor: 9.079

4.  Postantibiotic effect of sanfetrinem compared with those of six other agents against 12 penicillin-susceptible and -resistant pneumococci.

Authors:  S K Spangler; G Lin; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1997-10       Impact factor: 5.191

5.  Studies on the postantibiotic effect and the postantibiotic sub-MIC effect of meropenem.

Authors:  I Odenholt-Tornqvist
Journal:  J Antimicrob Chemother       Date:  1993-06       Impact factor: 5.790

6.  Postantibiotic sub-MIC effects of vancomycin, roxithromycin, sparfloxacin, and amikacin.

Authors:  I Odenholt-Tornqvist; E Löwdin; O Cars
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

7.  Susceptibilities of penicillin-susceptible and -resistant strains of Streptococcus pneumoniae to RP 59500, vancomycin, erythromycin, PD 131628, sparfloxacin, temafloxacin, win 57273, ofloxacin, and ciprofloxacin.

Authors:  S K Spangler; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

Review 8.  Management of infections caused by antibiotic-resistant Streptococcus pneumoniae.

Authors:  I R Friedland; G H McCracken
Journal:  N Engl J Med       Date:  1994-08-11       Impact factor: 91.245

9.  In vitro and in vivo antibacterial activities of levofloxacin (l-ofloxacin), an optically active ofloxacin.

Authors:  K P Fu; S C Lafredo; B Foleno; D M Isaacson; J F Barrett; A J Tobia; M E Rosenthale
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

10.  Increased rate of isolation of penicillin-resistant Streptococcus pneumoniae in a children's hospital and in vitro susceptibilities to antibiotics of potential therapeutic use.

Authors:  E O Mason; S L Kaplan; L B Lamberth; J Tillman
Journal:  Antimicrob Agents Chemother       Date:  1992-08       Impact factor: 5.191

View more
  17 in total

1.  Postantibiotic effects of grepafloxacin compared to those of five other agents against 12 gram-positive and -negative bacteria.

Authors:  S K Spangler; S Bajaksouzian; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2000-01       Impact factor: 5.191

2.  Gram-Positive Pneumonia.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-06       Impact factor: 3.725

3.  Antipneumococcal activities of gemifloxacin compared to those of nine other agents.

Authors:  T A Davies; L M Kelly; G A Pankuch; K L Credito; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

4.  In Vitro Activity of Gepotidacin (GSK2140944) against Neisseria gonorrhoeae.

Authors:  D J Farrell; H S Sader; P R Rhomberg; N E Scangarella-Oman; R K Flamm
Journal:  Antimicrob Agents Chemother       Date:  2017-02-23       Impact factor: 5.191

5.  Activities and postantibiotic effects of gemifloxacin compared to those of 11 other agents against Haemophilus influenzae and Moraxella catarrhalis.

Authors:  T A Davies; L M Kelly; D B Hoellman; L M Ednie; C L Clark; S Bajaksouzian; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

6.  Antipneumococcal activity of ABT-773 compared to those of 10 other agents.

Authors:  T A Davies; L M Ednie; D M Hoellman; G A Pankuch; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

7.  Bactericidal activity and postantibiotic effect of levofloxacin against anaerobes.

Authors:  S L Pendland; M Diaz-Linares; K W Garey; J G Woodward; S Ryu; L H Danziger
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

8.  Gepotidacin (GSK2140944) In Vitro Activity against Gram-Positive and Gram-Negative Bacteria.

Authors:  R K Flamm; D J Farrell; P R Rhomberg; N E Scangarella-Oman; H S Sader
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

9.  Reactive Oxygen Species Production Is a Major Factor Directing the Postantibiotic Effect of Fluoroquinolones in Streptococcus pneumoniae.

Authors:  M T García; M V Valenzuela; M J Ferrándiz; A G de la Campa
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

Review 10.  Levofloxacin. Its use in infections of the respiratory tract, skin, soft tissues and urinary tract.

Authors:  H D Langtry; H M Lamb
Journal:  Drugs       Date:  1998-09       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.